Modality
ERT
MOA
HER2
Target
MALT1
Pathway
Cell Cycle
Wet AMDNBEndometrial Ca
Development Pipeline
Preclinical
Sep 2020
→ Sep 2026
PreclinicalCurrent
NCT08540188
1,419 pts·Endometrial Ca
2022-05→2025-10·Active
NCT03369364
660 pts·NB
2020-09→2026-09·Not yet recruiting
2,079 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-255mo agoInterim· Endometrial Ca
2026-09-246mo awayInterim· NB
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Not yet…
Preclinical
Active
Catalysts
Interim
2025-10-25 · 5mo ago
Endometrial Ca
Interim
2026-09-24 · 6mo away
NB
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08540188 | Preclinical | Endometrial Ca | Active | 1419 | Safety |
| NCT03369364 | Preclinical | NB | Not yet recr... | 660 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 |